Last reviewed · How we verify

NCT03080948

Risk Stratification Among Individuals Who Have Many Moles on Their Skin

Completed Last updated 2 December 2025
What this trial tests

trial testing survey in High-Risk Nevus Phenotype in 73 participants. Completed in 28 November 2025.

Timeline
9 March 2017
Primary endpoint
28 November 2025
28 November 2025

Quick facts

Lead sponsorMemorial Sloan Kettering Cancer Center
StatusCompleted
Study typeOBSERVATIONAL
Enrollment73
Start date9 March 2017
Primary completion28 November 2025
Estimated completion28 November 2025
Sites4 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

Memorial Sloan Kettering Cancer Center — full company profile →

Who can join

18 and older, any sex, with High-Risk Nevus Phenotype. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The investigators are doing this study to improve our ability to identify which people with many moles on their skin are most likely to develop skin melanoma. The investigators hope to identify features of moles that are associated with melanoma risk. The investigators hope to use this information to customize and tailor melanoma screening to the individual patient based on a better estimate of their individual risk.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of survey

Trials testing the same drug.

Other Memorial Sloan Kettering Cancer Center trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03080948.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing